For additional information:Download the CHRYSALIS 2 Fact Sheet
Participants will receive the investigational medication or combination of investigational medications while completing various study tests and procedures.
All study-required visits, tests, and medications will be provided at no cost to qualified participants. The study will not pay for other medical care or current medication(s) needed to support your daily healthcare routine. In addition, reimbursement for study-required travel, meals, and parking may be available.
This initial appointment is an opportunity for you to:
Participants in CHRYSALIS 2 study will be assigned to different cohorts based on their mutational status. All participants in all cohorts will receive the same two investigational medications in combination and at the same dose. This is an open-label study, which means that you will know which investigational medications you are receiving. There is no placebo in this study.
You should make sure to inform your doctor of any new symptoms you experience while participating in the study. If you experience worsening of your disease at any time during the study, your study doctor will ask you to come to the study clinic to determine disease progression. If your disease is progressing, you will be asked to complete an end of study treatment visit 30 days after your last dose of investigational medication. You will then enter the follow-up phase with visits to the study clinic or telephone contact every 12 weeks until the end of study to find out how you are doing, if you have had any side effects, and if you have started any new cancer treatments.